Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, randomized, double-blinded, placebo controlled, dose escalation study of HH-120 in healthy adult volunteers. HH-120 is a novel inhalable biologic being developed for COVID-19 treatment. The study aims to evaluate the safety, tolerability and pharmacokinetic profile of HH-120 administered by aerosol inhalation after single and multiple ascending doses.

Clinical Trial Description

Approximately 48 participants will be sequentially enrolled into either 1 of 3 SAD cohorts (n=8 per cohort), or 1 of 3 MAD cohorts (n= 8 per cohort). An adaptive dose escalation schedule will be employed for both SAD and MAD parts of the study. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05116865
Study type Interventional
Source Huahui Health
Contact Qingping Chu
Phone +86.13810180939
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date November 2021
Completion date May 2022